News stories about Grifols SA, Barcelona (NASDAQ:GRFS) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Grifols SA, Barcelona earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.9599684506404 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several equities analysts have recently weighed in on the stock. Citigroup assumed coverage on shares of Grifols SA, Barcelona in a report on Tuesday, October 31st. They issued a “buy” rating for the company. BidaskClub raised shares of Grifols SA, Barcelona from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Zacks Investment Research raised shares of Grifols SA, Barcelona from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Finally, UBS Group lowered shares of Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a report on Friday, November 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $24.00.
Grifols SA, Barcelona (NASDAQ:GRFS) traded up $0.11 during mid-day trading on Friday, hitting $24.76. 357,848 shares of the company were exchanged, compared to its average volume of 532,463. Grifols SA, Barcelona has a 1 year low of $16.55 and a 1 year high of $24.85. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.39 and a current ratio of 3.17. The stock has a market capitalization of $6,440.00, a price-to-earnings ratio of 22.82, a PEG ratio of 1.65 and a beta of 1.03.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-grifols-sa-barcelona-grfs-stock-price.html.
About Grifols SA, Barcelona
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.